Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IK-175 Monotherapy and with Nivolumab in Advanced Solid Tumors and Urothelial Carcinoma
NCT04200963Phase 1Completed
- Sponsor
- ImageneBio
- Start
- Dec 2019
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of IK-175 in solid tumor and urothelial carcinoma (UC) (4 arms), sponsored by ImageneBio. Primary endpoints: Maximum Tolerated Dose or Maximum Administered Dose at 6 months and Safety and Tolerability (RP2D determination). Started Dec 2019; status: completed.
02
Drugs
IK-175
03
Conditions
solid tumorurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04200963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04200963.